These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 23018435

  • 1. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
    Massanella M, Negredo E, Puig J, Puertas MC, Buzón MJ, Pérez-Álvarez N, Carrillo J, Clotet B, Martínez-Picado J, Blanco J.
    AIDS; 2012 Nov 28; 26(18):2285-93. PubMed ID: 23018435
    [Abstract] [Full Text] [Related]

  • 2. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B.
    Antivir Ther; 2012 Nov 28; 17(2):355-64. PubMed ID: 22290239
    [Abstract] [Full Text] [Related]

  • 3. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.
    Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martínez-Picado J, Clotet B, Blanco J.
    J Antimicrob Chemother; 2013 Oct 28; 68(10):2358-62. PubMed ID: 23677919
    [Abstract] [Full Text] [Related]

  • 4. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.
    AIDS; 2012 Sep 24; 26(15):1885-94. PubMed ID: 22992577
    [Abstract] [Full Text] [Related]

  • 5. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.
    AIDS; 2012 Jan 14; 26(2):167-74. PubMed ID: 22089379
    [Abstract] [Full Text] [Related]

  • 6. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R.
    Antivir Ther; 2012 Jan 14; 17(7):1301-9. PubMed ID: 22948290
    [Abstract] [Full Text] [Related]

  • 7. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
    Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J, IntegRal Collaborative Group.
    J Acquir Immune Defic Syndr; 2013 Jun 01; 63(2):152-60. PubMed ID: 23392458
    [Abstract] [Full Text] [Related]

  • 8. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
    Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, Lewin SR, Haskelberg H, Kelleher AD, Garsia R, Boyd MA, Cooper DA, Emery S, CORAL Study Group.
    J Infect Dis; 2011 Nov 15; 204(10):1532-40. PubMed ID: 21930607
    [Abstract] [Full Text] [Related]

  • 9. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation.
    Kolber MA, Saenz MO, Tanner TJ, Arheart KL, Pahwa S, Liu H.
    Clin Immunol; 2008 Mar 15; 126(3):315-21. PubMed ID: 17997138
    [Abstract] [Full Text] [Related]

  • 10. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM, Schapiro JM, Winters MA, Merigan TC.
    AIDS Res Hum Retroviruses; 1998 May 01; 14(7):561-9. PubMed ID: 9591710
    [Abstract] [Full Text] [Related]

  • 11. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J, MaraviBoost Collaborative Group.
    AIDS; 2014 Jan 28; 28(3):325-34. PubMed ID: 24185044
    [Abstract] [Full Text] [Related]

  • 12. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI.
    Cytometry B Clin Cytom; 2007 Jan 15; 72(1):14-21. PubMed ID: 17041945
    [Abstract] [Full Text] [Related]

  • 13. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.
    Pallikkuth S, Fischl MA, Pahwa S.
    J Infect Dis; 2013 Nov 15; 208(10):1613-23. PubMed ID: 23922374
    [Abstract] [Full Text] [Related]

  • 14. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
    Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG.
    J Infect Dis; 2011 Apr 01; 203(7):960-8. PubMed ID: 21402547
    [Abstract] [Full Text] [Related]

  • 15. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
    Hey-Cunningham WJ, Murray JM, Natarajan V, Amin J, Moore CL, Emery S, Cooper DA, Zaunders J, Kelleher AD, Koelsch KK, PINT study team.
    AIDS; 2015 May 15; 29(8):911-9. PubMed ID: 25730509
    [Abstract] [Full Text] [Related]

  • 16. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V, Süsal C, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G.
    AIDS Res Hum Retroviruses; 2001 Mar 01; 17(4):329-35. PubMed ID: 11242519
    [Abstract] [Full Text] [Related]

  • 17. Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery.
    Massanella M, Gómez-Mora E, Carrillo J, Curriu M, Ouchi D, Puig J, Negredo E, Cabrera C, Clotet B, Blanco J.
    J Transl Med; 2015 Jul 17; 13():230. PubMed ID: 26183947
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 19. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 13; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 20. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.
    Asmuth DM, Ma ZM, Mann S, Knight TH, Yotter T, Albanese A, Melcher GP, Troia-Cancio P, Hayes T, Miller CJ, Pollard RB.
    AIDS; 2012 Aug 24; 26(13):1625-34. PubMed ID: 22820612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.